Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Botanical

or [[:Category:Antioxidants|Antioxidant]]

Use the filters below to narrow your results.

Codeine (2)

None (28) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Generic; huge OTC presence (1) · Generic; many OTC formulations (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Talwin (1) · Vicodin (1)

None (2) · Apomorphine and nuciferine; dopaminergic activity (1) · Contains atropine, scopolamine, hyoscyamine (1) · Contains bufotenin and DMT (1) · Contains harmine, harmaline, tetrahydroharmine (1) · Contains ibogaine; kappa-opioid agonist (1) · Contains LSA (2) · Contains mescaline (2) · Contains muscimol and ibotenic acid (1) · Contains psilocybin and psilocin (1) · Contains salvinorin A (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · DMT-containing plant used in psychedelic preparations (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Mechanism incompletely understood (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Partial MAOI; anticholinergic effects (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (4) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible MAO-A inhibitor; beta-carboline (1) · Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) · Weak serotonin reuptake inhibitor; beta-carboline (1)

None (38) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000012CE-QINU`"', '"`UNIQ--vote-000012CF-QINU`"', '"`UNIQ--vote-000012D0-QINU`"' (1) · '"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"' (1)

None (38) · Adult: 15–60 mg every 4 hours as needed. (1) · General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) · Replacement: 15-30 mg (22.5-45 IU) daily; NASH: 800 IU daily; AREDS-2: 400 IU daily (in combination formula) (1)

None (38) · 100, 200, 400 IU softgels and capsules; many proprietary OTC blends; combined formulations (AREDS-2) (1) · 100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (38) · 360 mg/day (1) · UL 1000 mg (~1500 IU natural)/d in adults; routinely exceeded in older AREDS-1 trials (1) · UL 2000 mg/d in adults (1)

None (38) · IV (1) · Oral (2) · PO (only formulation marketed in the US). (1)

None (38) · 30–60 min (PO) (1) · Days for symptom improvement in scurvy (1) · Days to weeks for tissue saturation (1)

None (38) · 4–6 hours (1) · Hours (1) · Weeks (fat-soluble) (1)

None (38) · 2.5–3 hours (1) · ~10-20 days (steady-state body pool); single dose plasma ~2 hours (1) · ~3-4 days plasma; adipose tissue stores last months (1)

None (38) · High with fat-containing meal; reduced in malabsorption (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~70-90% at typical doses; saturable at high doses (>500 mg) (1)

None (38) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Safe at replacement doses; high-dose use generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Safe at routine doses; routinely supplemented in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (38) · OTC in US (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)